1. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease;Chen;Cli Therapeutics,2007
2. Development and validation of a stability-indicating HPTLC method for analysis of rasagiline mesylate in the bulk drug and tablet dosage form;Kathirvel;Chr Res Int,2012
3. Peskin TB. Teva pharmaceutical Industries Ltd, Jerusalem, – rasagiline formulations of improved content uniformity, United States Patent 20060188581, Filed on 22-02-2006, Published on 24-08-2006.
4. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor;Thebault;Pharmacotherapy,2004
5. (–)–Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase;Tatton;J Neu Transm Supp,1996